Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AGIO Agios Pharmaceuticals	$36.70 +0.2%	$36.38	$23.42 ▼ $62.58	$2.13B	0.8	712,425 shs	155,235 shs
BHC Bausch Health Cos	$7.52 +4.8%	$6.25	$4.25 ▼ $9.85	$2.78B	0.41	2.43 million shs	2.32 million shs
OCUL Ocular Therapeutix	$12.67 +1.3%	$10.43	$5.78 ▼ $12.91	$2.20B	1.49	1.80 million shs	1.19 million shs
UPXI Upexi	$7.90 +0.8%	$6.69	$1.90 ▼ $22.57	$705.51M	-0.52	3.58 million shs	10.29 million shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AGIO Agios Pharmaceuticals	+3.48%	-2.94%	-6.68%	+29.55%	-18.84%
BHC Bausch Health Cos	+2.43%	+24.67%	+13.26%	+55.30%	+31.05%
OCUL Ocular Therapeutix	+0.16%	0.00%	+10.91%	+74.34%	+56.25%
UPXI Upexi	+17.57%	+39.57%	+31.38%	-18.27%	+85.55%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AGIO Agios Pharmaceuticals	4.2776 of 5 stars	3.4	1.0	4.3	3.3	0.8	1.9
BHC Bausch Health Cos	4.7035 of 5 stars	3.0	5.0	4.0	1.8	3.3	1.9
OCUL Ocular Therapeutix	3.7522 of 5 stars	3.5	1.0	4.1	2.9	1.7	0.0
UPXI Upexi	3.4342 of 5 stars	3.5	5.0	0.0	2.6	3.3	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AGIO Agios Pharmaceuticals	2.75	Moderate Buy	$56.33	53.49% Upside
BHC Bausch Health Cos	2.00	Hold	$9.00	19.76% Upside
OCUL Ocular Therapeutix	3.00	Buy	$17.20	35.81% Upside
UPXI Upexi	3.50	Strong Buy	$15.50	96.33% Upside

Current Analyst Ratings Breakdown

Latest UPXI, BHC, OCUL, and AGIO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/13/2025	UPXI Upexi	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
8/6/2025	OCUL Ocular Therapeutix	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Outperform ➝ Sector Outperform	$22.00 ➝ $20.00
8/5/2025	OCUL Ocular Therapeutix	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$14.00 ➝ $15.00
8/4/2025	UPXI Upexi	Alliance Global Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$15.00
7/28/2025	AGIO Agios Pharmaceuticals	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Outperform ➝ Sector Outperform	$71.00 ➝ $65.00
7/22/2025	AGIO Agios Pharmaceuticals	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$52.00 ➝ $51.00
6/16/2025	UPXI Upexi	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Overweight	$16.00
5/29/2025	OCUL Ocular Therapeutix	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$15.00

(Data available from 8/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AGIO Agios Pharmaceuticals	$36.50M	58.42	N/A	N/A	$23.57 per share	1.56
BHC Bausch Health Cos	$9.63B	0.29	$8.35 per share	0.90	$0.40 per share	18.79
OCUL Ocular Therapeutix	$63.72M	34.58	N/A	N/A	$1.76 per share	7.20
UPXI Upexi	$16.56M	42.60	N/A	N/A	$6.24 per share	1.27

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AGIO Agios Pharmaceuticals	$673.72M	$11.00	3.34	N/A	N/A	1,590.42%	-3.49%	-3.23%	10/30/2025 (Estimated)
BHC Bausch Health Cos	-$46M	$0.26	28.90	1.61	N/A	0.99%	-852.36%	5.25%	10/29/2025 (Estimated)
OCUL Ocular Therapeutix	-$193.51M	-$1.28	N/A	N/A	N/A	-382.51%	-71.92%	-49.36%	N/A
UPXI Upexi	-$23.66M	N/A	0.00	∞	N/A	-135.86%	-535.19%	-122.94%	9/29/2025 (Estimated)

Latest UPXI, BHC, OCUL, and AGIO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/5/2025	Q2 2025	OCUL Ocular Therapeutix	-$0.35	-$0.39	-$0.04	-$0.39	$13.12 million	$13.46 million
7/31/2025	Q2 2025	AGIO Agios Pharmaceuticals	-$1.74	-$1.93	-$0.19	-$1.93	$9.46 million	$12.50 million
7/30/2025	Q2 2025	BHC Bausch Health Cos	$0.97	$0.90	-$0.07	$0.40	$2.47 billion	$2.57 billion
5/16/2025	Q1 2025	UPXI Upexi	N/A	-$2.87	N/A	-$2.87	N/A	$3.16 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AGIO Agios Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
BHC Bausch Health Cos	N/A	N/A	N/A	N/A	N/A
OCUL Ocular Therapeutix	N/A	N/A	N/A	N/A	N/A
UPXI Upexi	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AGIO Agios Pharmaceuticals	N/A	14.48	14.04
BHC Bausch Health Cos	141.90	1.31	0.98
OCUL Ocular Therapeutix	0.23	10.10	10.02
UPXI Upexi	0.31	0.37	0.24

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AGIO Agios Pharmaceuticals	N/A
BHC Bausch Health Cos	78.65%
OCUL Ocular Therapeutix	59.21%
UPXI Upexi	5.68%

Insider Ownership

Company	Insider Ownership
AGIO Agios Pharmaceuticals	4.30%
BHC Bausch Health Cos	8.05%
OCUL Ocular Therapeutix	2.30%
UPXI Upexi	31.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AGIO Agios Pharmaceuticals	390	58.10 million	55.60 million	Optionable
BHC Bausch Health Cos	20,700	370.13 million	340.33 million	Optionable
OCUL Ocular Therapeutix	230	173.99 million	169.99 million	Optionable
UPXI Upexi	130	89.36 million	61.12 million	Optionable

UPXI, BHC, OCUL, and AGIO Headlines

Recent News About These Companies

Upexi establishes Advisory Committee, welcomes Hayes as first member

August 13 at 3:39 AM | msn.com

Former Amazon aggregator turns to Solana, records $70K in daily rewards

August 13 at 3:39 AM | msn.com

Upexi (NASDAQ:UPXI) Sees Unusually-High Trading Volume - Time to Buy?

August 12 at 3:43 PM | marketbeat.com

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Upexi, Inc. (NASDAQ: UPXI)

August 11 at 8:00 AM | prnewswire.com

Upexi (NASDAQ:UPXI) Shares Up 14.2% - Here's What Happened

August 9, 2025 | marketbeat.com

Crypto Currents: SEC eases staking rules as bitcoin miners pivot to AI

August 6, 2025 | msn.com

Alliance Global Partners Begins Coverage on Upexi (NASDAQ:UPXI)

August 6, 2025 | americanbankingnews.com

Upexi Surpasses 2 Million SOL in its Treasury

August 5, 2025 | taiwannews.com.twT

Solana Treasury Company Upexi Surpasses 2M in SOL Holdings

August 5, 2025 | coindesk.com

Upexi (NASDAQ:UPXI) Earns Buy Rating from Analysts at Alliance Global Partners

August 5, 2025 | marketbeat.com

Upexi, Inc. (NASDAQ:UPXI) Director Gene Salkind Buys 20,243 Shares

July 31, 2025 | marketbeat.com

Insider Buying: Upexi, Inc. (NASDAQ:UPXI) Director Acquires 20,243 Shares of Stock

July 31, 2025 | insidertrades.com

Upexi (NASDAQ:UPXI) Stock Price Down 9.9% - What's Next?

July 31, 2025 | marketbeat.com

Upexi to Participate in Fireside Chat at Canaccord Genuity’s 45th Annual Growth Conference on August 12th-14th

July 30, 2025 | manilatimes.netM

Upexi Secures $500M Equity Deal to Buy More Solana Despite Stock Drop

July 30, 2025 | thecurrencyanalytics.comT

Upexi enters $500M equity line agreement

July 29, 2025 | msn.com

Upexi, Inc. Announces $500 Million Equity Line Agreement with A.G.P. to Accelerate the Growth of its Solana Treasury Strategy

July 29, 2025 | manilatimes.netM

Solana Treasury firm Upexi secures $500M to acquire more SOL

July 29, 2025 | msn.com

Upexi (NASDAQ:UPXI) Shares Gap Up - Here's Why

July 28, 2025 | marketbeat.com

Traders Buy Large Volume of Call Options on Upexi (NASDAQ:UPXI)

July 28, 2025 | marketbeat.com

Insider Buying: Upexi, Inc. (NASDAQ:UPXI) Director Acquires 4,000 Shares of Stock

July 25, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

UPXI, BHC, OCUL, and AGIO Company Descriptions

Agios Pharmaceuticals NASDAQ:AGIO

$36.70 +0.09 (+0.25%)

Closing price 03:59 PM Eastern

Extended Trading

$36.40 -0.31 (-0.83%)

As of 04:10 PM Eastern

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Bausch Health Cos NYSE:BHC

$7.52 +0.35 (+4.81%)

Closing price 03:59 PM Eastern

Extended Trading

$7.52 0.00 (0.00%)

As of 04:10 PM Eastern

Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products in the United States. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products internationally. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; generic products; ortho dermatologic; and dentistry products in the United States. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.

Ocular Therapeutix NASDAQ:OCUL

$12.66 +0.17 (+1.32%)

Closing price 03:59 PM Eastern

Extended Trading

$12.66 0.00 (-0.04%)

As of 04:10 PM Eastern

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.

Upexi NASDAQ:UPXI

$7.90 +0.07 (+0.83%)

Closing price 03:59 PM Eastern

Extended Trading

$7.81 -0.08 (-1.06%)

As of 04:14 PM Eastern

Upexi, Inc. manufactures and sells various branded products in the health, wellness, pet, beauty, and other markets. The company was formerly known as Grove, Inc. and changed its name to Upexi, Inc. in August 2022. The company was incorporated in 2018 and is headquartered in Clearwater, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time